Cargando…
Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer
BACKGROUND: An ever‐increasing number of efforts are focused on identifying effective biomarkers for immune checkpoint inhibitors (ICIs). Cytokines and chemokines are critical to tumor growth, metastasis, tumor angiogenesis, and the immune response against tumor cells. In the study here, we determin...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278479/ https://www.ncbi.nlm.nih.gov/pubmed/37062076 http://dx.doi.org/10.1002/cam4.5918 |
_version_ | 1785060494965473280 |
---|---|
author | Hu, Yue Li, Shixun Xiao, He Xiong, Yanli Lu, Xianfeng Yang, Xiao Luo, Wei Luo, Jiamin Zhang, Shiheng Cheng, Yi Zhang, Lei Dai, Xiaoyan Yang, Yuxin Wang, Dong Li, Mengxia |
author_facet | Hu, Yue Li, Shixun Xiao, He Xiong, Yanli Lu, Xianfeng Yang, Xiao Luo, Wei Luo, Jiamin Zhang, Shiheng Cheng, Yi Zhang, Lei Dai, Xiaoyan Yang, Yuxin Wang, Dong Li, Mengxia |
author_sort | Hu, Yue |
collection | PubMed |
description | BACKGROUND: An ever‐increasing number of efforts are focused on identifying effective biomarkers for immune checkpoint inhibitors (ICIs). Cytokines and chemokines are critical to tumor growth, metastasis, tumor angiogenesis, and the immune response against tumor cells. In the study here, we determined the correlation between circulating cytokines/chemokines and the clinical benefit of ICIs for non‐small cell lung cancer (NSCLC) patients. METHODS: Peripheral blood samples were collected before and during treatment (at 12th week). Plasma levels of cytokines/chemokines and specific stress response markers were measured using the Bio‐Plex Pro Human Cytokines Grp I Panel (27‐plex), an APEX1 detection kit, and a human LAP(TGF‐β1) immunoassay kit. A Mann–Whitney U‐test or Wilcoxon signed‐rank test and a Cox proportional hazards model were employed for statistical analysis. RESULTS: In the ICI monotherapy cohort, a high level of IL‐6 at pretreatment or an elevation of IL‐6, IL‐8, FGF2, CXCL10, CCR1, PDFGB, TNF, and APEX1 posttreatment was associated with poor progress‐free survival (PFS). A posttreatment elevation (defined herein as change rate) of CXCL10 was also associated with poor overall survival (OS). In the combinational therapy group, a high level of IL‐12, IL‐17A, FGF2, VEGF, and APEX1 at pretreatment and an elevation of CCL2 posttreatment were associated with poor PFS. A high level of IL‐9, FGF2, PDFGB, CCL4, TFGB, and APEX1 at pretreatment and an elevation of IL‐13, CSF2, and CCL2 at posttreatment were associated with poor OS of patients receiving combination therapy. CONCLUSIONS: The study here suggests that circulating cytokines/chemokines are feasible, noninvasive biomarkers for predicting clinical benefit of ICI treatment for NSCLC. Distinct circulating factor profiles were observed in individuals receiving ICI monotherapy or combination therapy. |
format | Online Article Text |
id | pubmed-10278479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102784792023-06-20 Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer Hu, Yue Li, Shixun Xiao, He Xiong, Yanli Lu, Xianfeng Yang, Xiao Luo, Wei Luo, Jiamin Zhang, Shiheng Cheng, Yi Zhang, Lei Dai, Xiaoyan Yang, Yuxin Wang, Dong Li, Mengxia Cancer Med RESEARCH ARTICLES BACKGROUND: An ever‐increasing number of efforts are focused on identifying effective biomarkers for immune checkpoint inhibitors (ICIs). Cytokines and chemokines are critical to tumor growth, metastasis, tumor angiogenesis, and the immune response against tumor cells. In the study here, we determined the correlation between circulating cytokines/chemokines and the clinical benefit of ICIs for non‐small cell lung cancer (NSCLC) patients. METHODS: Peripheral blood samples were collected before and during treatment (at 12th week). Plasma levels of cytokines/chemokines and specific stress response markers were measured using the Bio‐Plex Pro Human Cytokines Grp I Panel (27‐plex), an APEX1 detection kit, and a human LAP(TGF‐β1) immunoassay kit. A Mann–Whitney U‐test or Wilcoxon signed‐rank test and a Cox proportional hazards model were employed for statistical analysis. RESULTS: In the ICI monotherapy cohort, a high level of IL‐6 at pretreatment or an elevation of IL‐6, IL‐8, FGF2, CXCL10, CCR1, PDFGB, TNF, and APEX1 posttreatment was associated with poor progress‐free survival (PFS). A posttreatment elevation (defined herein as change rate) of CXCL10 was also associated with poor overall survival (OS). In the combinational therapy group, a high level of IL‐12, IL‐17A, FGF2, VEGF, and APEX1 at pretreatment and an elevation of CCL2 posttreatment were associated with poor PFS. A high level of IL‐9, FGF2, PDFGB, CCL4, TFGB, and APEX1 at pretreatment and an elevation of IL‐13, CSF2, and CCL2 at posttreatment were associated with poor OS of patients receiving combination therapy. CONCLUSIONS: The study here suggests that circulating cytokines/chemokines are feasible, noninvasive biomarkers for predicting clinical benefit of ICI treatment for NSCLC. Distinct circulating factor profiles were observed in individuals receiving ICI monotherapy or combination therapy. John Wiley and Sons Inc. 2023-04-16 /pmc/articles/PMC10278479/ /pubmed/37062076 http://dx.doi.org/10.1002/cam4.5918 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Hu, Yue Li, Shixun Xiao, He Xiong, Yanli Lu, Xianfeng Yang, Xiao Luo, Wei Luo, Jiamin Zhang, Shiheng Cheng, Yi Zhang, Lei Dai, Xiaoyan Yang, Yuxin Wang, Dong Li, Mengxia Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer |
title | Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer |
title_full | Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer |
title_fullStr | Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer |
title_full_unstemmed | Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer |
title_short | Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer |
title_sort | distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278479/ https://www.ncbi.nlm.nih.gov/pubmed/37062076 http://dx.doi.org/10.1002/cam4.5918 |
work_keys_str_mv | AT huyue distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT lishixun distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT xiaohe distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT xiongyanli distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT luxianfeng distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT yangxiao distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT luowei distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT luojiamin distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT zhangshiheng distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT chengyi distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT zhanglei distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT daixiaoyan distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT yangyuxin distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT wangdong distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer AT limengxia distinctcirculatingcytokinechemokineprofilescorrelatewithclinicalbenefitofimmunecheckpointinhibitormonotherapyandcombinationtherapyinadvancednonsmallcelllungcancer |